Liposomal Doxorubicin and Bortezomib for Relapsed or Refractory Multiple Myeloma

Orlowski R.Z. , Nagler A. , Sonneveld P. . Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007; 25(25): 3892–3901.

Sonneveld P. , Hajek R. , Nagler A. .; the DOXIL-MMY-3001 Study Investigators. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer. 2008; 112(7): 1529–1537.

Orlowski R.Z. , Zhuang S.H. , Parekh T. .; the DOXIL-MMY-3001 Study Investigators. The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared to bortezomib alone: results from a planned interim analysis of a randomized phase III study [abstract 404]. Blood. 2006. http://abstracts.hematologylibrary.org/cgi/content/abstract/108/11/404?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=orlowski&searchid=1&FIRSTINDEX=10&volume=108&issue=11&resourcetype=HWCIT. Accessed September 4, 2009.

Harousseau J.L. , Nagler A. , Sonneveld P. .; for the DOXIL-MMY-3001 Study Investigators. Effect of the combination of pegylated doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone [abstract 8002]. ASCO. 2007. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=34998. Accessed September 4, 2009.

Blade J. , Sonneveld P. , San Miguel J. . The effect of pegylated liposomal doxorubicin plus bortezomib in multiple myeloma patients with renal insufficiency [abstract 8562]. ASCO. 2008. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=33373. Accessed September 2009.

Orlowski R.Z. , Voorhees P.M. , Garcia R.A. . Phase 1 trial of proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005; 105(8): 3058–3065.

Orlowski R.Z. , Peterson B.L. , Sanford B. .; the Cancer Leukemia Group. Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: cancer and leukemia group B study 10301 [abstract 797]. Blood. 2006. http://abstracts.hematologylibrary.org/cgi/content/abstract/108/11/797?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=orlowski&searchid=1&FIRSTINDEX=0&volume=108&issue=11&resourcetype=HWCIT. Accessed September 4, 2009.

National Cancer Comprehensive Network. NCCN clinical practice guidelines in oncology. Multiple myeloma. v.2.2010. http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf. Published 2009. Accessed October 13, 2009.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Antiemesis. v.4.2009. http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Published 2009. Accessed October 4, 2009.

Kris M.G. , Hesketh P.J. , Somerfield M.R. .; American Society of Clinical Oncology. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006; 24(18): 2932–2947.

Multinational Association for Supportive Care in Cancer. Antiemetic guidelines. http://data.memberclicks.com/site/mascc/MASCC_Guidelines_Update.pdf. Published 2004. Updated March 2008. Accessed October 9, 2009.

Terrey J.P. , Aapro M.S. The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res. 1996; 8: 281–288.

Carmichael J. , Keizer H.J. , Cupissol D. , Milliez J. , Scheidel P. , Schindler A.E. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs. 1998; 9(5): 381–385.

de Wit R. , de Boer A.C. , vd Linden G.H. , Stoter G. , Sparreboom A. , Verweij J. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001; 85(8): 1099–1101.

Smith IE; the Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. J Cancer Res Clin Oncol. 1993; 119(6): 350–354.

Soukop M. the Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer. 1994; 2(3): 177–183.

Doxil [package insert]. Bedford, OH: Ben Venue Laboratories Inc; 2007.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Myeloid growth factors. v.1.2009. http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf. Published 2009. Accessed October 9, 2009.

Smith T.J. , Khatcheressian J. , Lyman G.H. . 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol. 2006; 24(19): 3187–3205.

Larson D.L. Treatment of tissue extravasation by antitumor agents. Cancer. 1982; 49(9): 1796–1799.

Larson D.L. What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg. 1985; 75(3): 397–402.

Mullin S. , Beckwith C. , Tyler L. Prevention and management of antineoplastic extravasation injury. Hosp Pharm. 2000; 35: 57–74.

Velcade [package insert]. Cambridge, MA: Millennium Pharmaceuticals Inc: 2008.

Boyiadzis M.M. , Lebowitz P.F. , Frame J.N. , Fojo T. Hematology-Oncology Therapy. New York, NY: McGraw-Hill; 2007; 570–578.